Blinatumomab-induced remission followed by haploidentical transplantation in pediatric relapsed/refractory pre-B ALL: a multicenter study in Mexico
Blinatumomab followed by haploidentical HSCT offers an effective and feasible therapeutic strategy for *relapsed or refractory CD19+ pre-B ALL* in *Mexico*, improving long-term survival in resource-limited settings.
Authors
- Nideshda Ramírez-Uribe
- Annecy Nelly Herver-Olivares
- Haydeé Salazar-Rosales
- Alberto Olaya‐Vargas (ORCID: https://orcid.org/0000-0002-1506-6753)
- Ignacio Mora‐Magaña
- Martín Pérez-García (ORCID: https://orcid.org/0000-0002-4545-9435)
- César Alejandro Galván‐Díaz (ORCID: https://orcid.org/0000-0003-0154-5339)
- Ángeles Del Campo-Martínez
- Jaime Shalkow‐Klincovstein
- Pilar Cubria-Juárez
- Rocío Cárdenas‐Cardós (ORCID: https://orcid.org/0000-0002-4390-5892)
- Norma López‐Santiago
- Gerardo López‐Hernández (ORCID: https://orcid.org/0000-0002-2586-9031)
- Yadira Melchor-Vidal
- Carlos Gallardo (ORCID: https://orcid.org/0000-0001-6516-395X)
- Irlanda Campos-Pérez
Institutions
- Mexican Social Security Institute (MX)
- Cell Technology (China) (HK)
- Centro Médico ABC (MX)
- Vietnam National Children's Hospital (VN)
- Statistical Service (CY)
- The Japanese Data Center for Hematopoietic Cell Transplantation (JP)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.3389/fonc.2025.1653329
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00